We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

109 hedge funds and large institutions have $103M invested in Enanta Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 38 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

12% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 17

2% more funds holding

Funds holding: 107 → 109 (+2)

3% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 38

6.63% less ownership

Funds ownership: 93.95% → 87.32% (-6.6%)

10% less capital invested

Capital invested by funds: $114M → $103M (-$11.7M)

56% less call options, than puts

Call options by funds: $35K | Put options by funds: $79K

Holders
109
Holders Change
+2
Holders Change %
+1.87%
% of All Funds
1.46%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
19
Increased
37
Reduced
38
Closed
17
Calls
$35K
Puts
$79K
Net Calls
-$44K
Net Calls Change
-$29K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$2.78M
2
AQR Capital Management
AQR Capital Management
Connecticut
+$1.92M
3
SCM
Stonepine Capital Management
Oregon
+$1.6M
4
TI
Trexquant Investment
Connecticut
+$952K
5
SFI
Susquehanna Fundamental Investments
Pennsylvania
+$464K

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$5.97M
2
Morgan Stanley
Morgan Stanley
New York
-$4.55M
3
CP
Caligan Partners
New York
-$1.06M
4
Citadel Advisors
Citadel Advisors
Florida
-$577K
5
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$495K
Name Holding Trade Value Shares
Change 		Change in
Stake
FCM
1
Farallon Capital Management
California
$11.7M +$86.5K +14,000 +0.7%
KAM
2
Krensavage Asset Management
New York
$11.7M -$4.97K -804 -0%
BlackRock
3
BlackRock
New York
$11.1M -$130K -20,973 -1%
Vanguard Group
4
Vanguard Group
Pennsylvania
$11.1M +$144K +23,269 +1%
Millennium Management
5
Millennium Management
New York
$7.44M +$2.78M +449,945 +50%
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$4.78M +$109K +17,613 +2%
Marshall Wace
7
Marshall Wace
United Kingdom
$4.7M -$489K -79,197 -9%
SCM
8
Stonepine Capital Management
Oregon
$3.26M +$1.6M +258,842 +78%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$2.73M +$105K +16,974 +4%
Morgan Stanley
10
Morgan Stanley
New York
$2.68M -$4.55M -736,104 -60%
Renaissance Technologies
11
Renaissance Technologies
New York
$2.56M -$212K -34,400 -7%
State Street
12
State Street
Massachusetts
$2.51M -$34.5K -5,590 -1%
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$2.12M -$236K -38,274 -9%
AQR Capital Management
14
AQR Capital Management
Connecticut
$1.97M +$1.92M +311,010 +675%
Northern Trust
15
Northern Trust
Illinois
$1.77M -$413K -66,864 -17%
TI
16
Trexquant Investment
Connecticut
$1.6M +$952K +154,105 +113%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$1.56M -$91.4K -14,804 -5%
Jacobs Levy Equity Management
18
Jacobs Levy Equity Management
New Jersey
$1.47M -$144K -23,243 -8%
SCM
19
Sio Capital Management
New York
$977K – – –
Charles Schwab
20
Charles Schwab
California
$882K +$30.7K +4,974 +3%
UBS AM
21
UBS AM
Illinois
$880K -$1.43K -232 -0.1%
Two Sigma Advisers
22
Two Sigma Advisers
New York
$806K -$63K -10,200 -7%
JP Morgan Chase
23
JP Morgan Chase
New York
$741K -$179K -28,911 -18%
Goldman Sachs
24
Goldman Sachs
New York
$720K +$40.5K +6,549 +5%
TCM
25
Tang Capital Management
California
$699K – – –
1
2 3 4 5

ENTA Hedge Fund Activity: Q1 2025 in Review

109 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2025, worth a combined $103M — down 10% from $114M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ENTA positions and 17 closed out — a net gain of 2 holders — while 37 added to existing stakes and 38 trimmed.

The largest buyer was Millennium Management, adding an estimated $2.78M. The largest seller was RA Capital Management, exiting entirely with an estimated $5.97M sold.

  • 109 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2025, up from 107 in Q4 2024.
  • Funds reported $103M of Enanta Pharmaceuticals stock for Q1 2025, down 10% quarter-over-quarter.
  • 19 funds opened new Enanta Pharmaceuticals positions in Q1 2025 and 17 closed out, a net change of +2 holders.
  • The largest Enanta Pharmaceuticals buyer in Q1 2025 was Millennium Management, an estimated $2.78M added.
  • The largest Enanta Pharmaceuticals seller in Q1 2025 was RA Capital Management, an estimated $5.97M sold.

Based on aggregated 13F filings for Q1 2025.